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Gene Regulation and Genetic Susceptibility
to Neoplastic Transformation: AP-1 and p80
Expression in JB6 Cells
by Lori R. Bernstein,* Elia T. Ben-Ari,* Stephanie L.
Simek,*t and Nancy H. Colburn*
The mouse epidermal JB6 cell system consists of clonal genetic variants that are sensitive (P+) or
resistant (PW) to the promotion ofneoplastic transformation by phorbol esters and othertumor-promoting
agents. P+ cells display AP-1-dependent phorbol-ester-inducible transactivation of gene expression,
whereas P- cells have a defect in transactivation. Transfection of promotion sensitivity gene pro-1 into
P- cells reconstituted both P+ phenotype and AP-1-dependent phorbol-ester-inducible transactivation. P-
and P+ cells exhibited induction of c-jun and c-fos messenger RNA levels by phorbol ester, but P- cells
had significantly lower basal and induced levels ofjun mRNA than P4 cells. Basal and induced levels of
c-jun protein were significantly lower in P- cells as well. Differences in levels the 80-kDa pI 4.5 protein
p80 were also observed in JB6 cells as a function of preneoplastic progression; high levels of p80 protein
and mRNA were observed in P- cells, intermediate levels in P4 cells, and negligible levels were observed
in transformed derivatives ofJB6 cells. Phorbol estertreatment inducedphosphorylation but not synthesis
of p80. These data are consistent with the hypotheses that AP-1 is required in the signal transduction
pathway for promotion ofneoplastic transformation by tumor promoter, thatpro genes may control AP-
1 activity, thatthreshold levels ofJun mRNA and protein may play arole intransactivation and promotion
sensitivity, and that the p80 protein in JB6 cells may behave in vivo as a suppressor of cellular transfor-
mation.
Introduction
Recent progress in understanding the genetics of
susceptibility to tumor promotion has come from in
vivo studies in the mouse by Drinkwater (1), Di-
Giovanni (2), Gould et al. (3), and Malkinson (4) and
from studies with mouse epidermal JB6 cell variants
in our laboratory and those of others. The JB6 cell
lines were derived from untreated primary BALB/c
mouse epidermal cell cultures that gave rise at a very
low frequency to immortalized cell lines (5). The im-
mortalizedJB6 cells underwent furtherchange to sta-
bly acquire sensitivity to induction of anchorage in-
dependence andtumorigenicitybyphorbolesters such
as tetradecanoyl phorbol-13-acetate (TPA) and other
tumor promoters (5,6). Nonselective cloning soon
after observation of this change yielded clonal lines
that were stably sensitive (P+) or resistant (P-) to
tumor-promoter-induced neoplastic transformation
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(7-9). The percentage of cells in agar that display
TPA-induced anchorage independence is typically in
the range of20% for P+ cells and 0.2% or less for P-
cells. These JB6 variants sensitive to tumor-pro-
moter-induced transformation appear to undergo a
transitionanalogous tosecond-stagetumorpromotion
in vivo since second-stage tumor promoters such as
mezerein induce transformation, and second-stage in-
hibitors, such as retinoids, but not first-stage inhibi-
tors, such as antiproteases, block the induced trans-
formation (10).
Table 1 summarizes the results ofanumberofstud-
ies that have used the P+ and P- variants to identify
steps that may be required in the signal transduction
pathway for promoter-induced transformation. Can-
didatesforrequiredeventswouldbeexpectedtoshow
a P4/P- differential in some or all clonal variants
tested; responses not showing a P+/P- differential
may or may not be required ones. P+ and P- cells
showed similar responses to mitogenic stimulation by
phorbol esters, and displayed similarinductionofpro-
tease activity. They also showed similar levels ofpro-
tein kinase C activity. Whether there are protein
kinase C subtype differences has not yet been estab-
lished.BERNSTEIN ET AL.
Table 1. Biochemical and genetic responses to tumor promoters
in P+ and P- cells.
P+ and P- cells show the following similar responses to tumor
promoters:
Mitogenic stimulation from quiescence (11)
Decreased synthesis of collagen, fibronectin (21-23)
Induction of proteases: major excreted protein and plasminogen
activator (N. H. Colburn and K. Hirano, unpublished)
Increased glucose uptake and ornithine decarboxylase
activity (24,25)
Similar protein kinase C activation and substrates (10,12,13)
What distinguishes P+ from P- cells?
Activated versus inactive pro 1 and pro 2 (14,15,26)
Levels of an 80-kDa/pI 4.5 phosphoprotein (10,13,20)
Ganglioside synthesis response to TPA (16,27)
Induction of AP-1/jun-dependent transactivation of gene
expression (19) andjun mRNA and protein levels
Induction of 15-kDa and 16-kDa nuclear proteins (K. Hirano and
N. H. Colburn, in preparation)
DNA damage and poly ADP ribosylation responses (18)
JB6 P+ but not P- cells possess activated DNA
sequences called pro 1 and pro2thatconfersensitivity
to tumor-promoter-induced transformation when
transferred into P- cells (14). Pro 1 appears to encode
a transcript whose synthesis is catalyzed by RNA po-
lymerase III (15). The mode of activation of pro 1 to
a P+ active structure is not yet known. P+/P- differ-
ences in TPA modulated ganglioside synthesis (16)
and induced synthesis of 15 and 16 kDa nuclear pro-
teins (K. Hirano, B. Smith, and N.H. Colburn, in
preparation) have also been observed. Nakamura et
al. have reported that treatment ofJB6 P+ cells with
xanthine-xanthine oxidase, which generates super-
oxideanionand subsequently otheractive oxygen spe-
cies, promotes neoplastic transformation (17). Cerutti
and co-workers have found that JB6 P- cells show a
greater DNA damage and ADP ribosylation response
to transformation-promoting xanthine-xanthine oxi-
dase treatment than do P+ cells (18). These results
suggest that greater oxidant defense may be an im-
portant component ofthe P+ phenotype. Finally, Ta-
ble 1 shows two other sets of genes whose expression
and/oractivityis differential inP+ and P- cells. These
are the AP-1 transactivating complex composed of
members of the jun and fos multigene families (19),
and an 80-kDa pI 4.5 protein (p80). The present com-
munication focuses on AP-1 and p80 and their roles in
preneoplastic progression in JB6 cells.
AP-1/jun-Mediated Transactivation
of Gene Expression Is Differentially
Induced by Tumor-Promoting
Agents in P+ Cells and P- Cells
TPA treatment of cells induces the expression of a
number of genes, some of which encode proteins
thought to be key participants in implementing neo-
plastic transformation (28,29). The list of such TPA-
inducible genes includes several proto-oncogenes, in-
cluding c-myc and c-fos, proteases, including colla-
genase, stromelysin and plasminogen activator, nu-
merous virally encoded genes, and other sequences
(28,29). Investigation ofthe identities of trans-regu-
latory factors that would be predicted to exist and to
control cis enhancerelements inthe promoterregions
ofthese sequences led to the discovery ofAP-1 tran-
sactivating protein (30,31). The complex consists ofa
heterodimeric species containing products ofthejun
andfos multigene families (32-35); homodimeric Jun
protein complexes have also been detected (35).
TPA induces AP-1 bindingto aconsensus upstream
regulatory enhancer sequence (TGACTCA) in several
genes thought to be involved in oncogenesis (30). The
binding of AP-1 to its enhancer is likely to regulate
transcription of these genes. We therefore hypothe-
sized that AP-1 function is specifically required for
the promotion phase of neoplastic transformation. If
AP-1 controls a set of effector genes required for tu-
mor-promoter-induced transformation, then some
promotion-resistant variants may owe their resist-
ance to a defect in tumor promoter inducibility ofAP-
1 function.
To investigate this hypothesis, mouse JB6 P+ and
P- variants were treated with TPA after transient
transfection with plasmid 3XTRE-CAT, a construct
that has three tandem TPA-responsive cis-enhancer
elements attached to the Herpes simplex virus thy-
midine kinase (HSV-TK) promoter and a gene encod-
ingchloramphenicol acetyltransferase (CAT) (30). In-
duced CAT gene expression in this system depends
upon tumor-promoter-mediated activation of cellular
AP-1 activity. This system enabled us to test the pre-
diction that cellular genetic variants resistant to the
promotion ofneoplastictransformationbyTPAwould
possess defective AP-1 transactivation function (19).
As shown in Figure 1A, P+ Cl 41 cells displayed
significantinducibleAPl-dependentCATproteinsyn-
thesis within 3.5 hr ofTPA treatment (but not within
1.5 hr). TPA-induced expression of CAT reached a
maximum of 900 to 1000 units of enzyme activity in
the P+ Cl 41 cells after 48 hr (5- to 6-fold induction)
and was persistent over at least 100 hr. In contrast,
P- Cl 30 cells showed little inducibilityby TPAat any
time point tested from 0 to 100 hr. Uptake of the
transfected 3XTRE-CAT plasmid in the R+ and P-
cells was equalized as measured by Southern hybrid-
ization analysis of transient transfectants (19) (not
shown). Furthermore, equal levels of CAT activity
were observed in P+ Cl 41 cells and P- Cl 30 cells
transfected withtheconstitutively expressedplasmid
pRSVCAT at doses suchthat DNAuptake(copies per
cell) was equalized. APi-dependent CAT synthesis
was also induced in P+ cells but not in P- cells by
epidermal growth factor (EGF) and by high concen-
trations ofserum, two additional transformation pro-
moting agents for JB6 cells (19) (not shown). These
data point to a specific regulatory defect at the level
ofAP-1 functioninthepromotionresistant Cl 30cells.
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FIGURE 1. TPA induces APi-dependent CAT synth
but not in P- cells. (A) Differential CAT inductio
cells and P- Cl 30 cells. P+ Cl 41 cells and P- Cl
plated, TPAtreated in2%fetalcalfserum, harveste
for CAT enzyme activity as described (19). TPA a
ventDMSOtreatments wereconducted ateachtime
showing differential inducibility were obtained in t
dent experiments. Data from a representative e:
plotted as units ofCAT enzyme activity per 4 x 10
cells divided by the activity for 4 x 104 DMSO-t:
that time point. One unit of CAT enzyme activit3
activity required to catalyze acetate transfer to ci
at a rate of5.4 fmole/min. at 37°C. (B) Differential'
CAT synthesis in P+ clonal pro 1 transfectants and
and Cl 25 cells. Clonal P+ transfectants, designat
were generated as described in the text. Cells we:
assayed over time courses of TPA treatment as d
and results are plotted as fold induction versus time
ment.
DifferentialAPl-dependent CAT gene r(
P+ and P- cells was also observed in tw
dently derived clonal JB6 P+ and P- cell
is shown in Figure 1B. The independent I
is designated Cl 25, and its time course f
pendent CAT synthesis as a function of'
ment reveals nonresponsiveness, as was c
the P- Cl 30 cell line. The P+ clonal variant, desig-
nated pNP-20, was derived from parental P- Cl 30
cells by ring cloning of G418-selected transfectants
> C141,TPA generated by introduction ofa plasmid construct har- boringthemousepromotionsensitivitygenepro 1(28)
and a neomycin resistance marker. This variant dis-
played anchorage-independent colony formationupon
Cl41,DMSO TPA treatment in soft agar (not shown). As shown in
-,C130'DTPA Figure 1B, this P+ pro 1 transfectant cell line exhib-
100 ited TPA-inducible CAT gene expression over a 48-
hr time course, with a linear increase from 0 to 48 hr.
In contrast, the P- recipient cells did not display in-
duced expression. Note that transfectants harboring
the neo resistance marker have shown no ability to
activate AP-1 function (36).
Observation of defective AP-1 function in two in-
pNP-20 (P+) dependent P- clonal variants and ofcompetent AP-1
function in two independent P+ clonal variants dem-
onstrates an association between AP-1 function and
promotion oftransformation. It is consistent with the
hypothesis that AP-1 function is required along the
signal transduction pathway for promotion of neo-
plastictransformationbyTPA. Furthermore, thefact
that introduction ofa gene that confers sensitivity to
Cl 30 (P-) promotion of transformation by TPA reconstitutes
0230 (P-) AP-1 function to a defective P- cell supports the hy-
pothesis that pro genes can execute control over the
activity of AP-1.
Measurement ofjun and fos mRNA
Levels in P+ and P- Cells
TPA stimulates the accumulation of c-jun mRNA
esis in P+ es in murine and human fibroblasts (42,43) and induces
)ns in P+ cells transcription ofthe c-fos gene in a number ofsystems
130 cells were (44). Therefore, the possibility that differential AP-1
,d, andassayed dependent transactivation in P+ and P cells was due
nd control sol- to differences in expression of c-jun or c-fos was ex- point. Results amined. Total RNA was isolated from JB6 cells at
xperiment are various times after treatment with 10 ng/mL TPA,
}4TPA-treated and the relative levels of c-jun or c-fos mRNA were
reated cells at determined by Northern blotting and densitometry
ylordepfihendicol scanning analyses of the resulting autoradiographs
TPA-inducible (Fig. 2, upperpanel). TPA-induced c-jun mRNA lev-
P- recipients els were higherin P+ cellsthaninP- cells atalltimes
ted pNP cells, afteradditionofTPA, andbasallevelsofthismessage
re treated and werealso5-to 10-foldhigherintheP+ cells. Inseveral lescribed in A,
ofTPAtreat- experiments c-jun mRNA was undetectable in un-
treated P- cells. After 24 hr, the amount of c-jun
mRNA returned to basal levels in the P+ cells, but
remained slightly elevated in P- cells.
egulationin In contrast to the results obtained for c-jun, TPA-
ro indepen- stimulated levels of c-fos mRNA were essentially
variants, as equal in P+ and P- cells (Fig. 2, lower panel). Basal
P- cell line c-fos mRNA levels were 2.5- to 10-fold higher in the
or APl-de- P- cells. The degree ofinduction ofc-fos message by
TPA treat- TPA was much greater than that observed for c-jun,
)bserved in and the levels of c-fos mRNA declined much more
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rapidlythanthose ofc-junmRNA, returningto near-
basal amounts after 2 hr of TPA treatment.
The above results suggest that the differential trans-
activation observed in response to TPA in promotion-
sensitive and resistant JB6 cells may be accounted for
at least in part by differences in TPA-stimulated ac-
cumulationofc-junmRNA. However, differentialTPA-
induced expression of c-fos, at least at the message
level, can be ruled out as a contributor to the observed
differences in AP-1-dependent transactivation. While
AP-1-dependent transactivation via the 3XTRE in re-
lp+ sponsetoTPAisvirtuallyundetectableinP- cells, TPA
still stimulates c-jun mRNA accumulation to a signifi-
cant degree inthese cells. Itis possible that athreshold
iP- level of c-jun mRNA and protein must be reached in
order to stimulate AP-1 dependent transactivation
above basal levels.
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0. Expression of Jun Protein in JB6
P+ and P- Cells
o0 i'; To determine whether phenotypic differences in c-
jun mRNA levels are also observable at the protein
11 \ \\T level, Westernimmunoblottinganalyses ofnuclearlys-
9 ~ll \ l ates from TPA-treated P+ and P- cells were conducted
I Nuclear proteins from TPA treated cells (10 ng/mL
6 p- TPA) and untreated cells were run on 10% Laemmli
\ SDS-PAGE gels, transferred onto nitrocellulose filters,
and immunoblotted with affinity purified rabbit anti-
4 +\ \ PEP-2 Jun peptide antiserum (38) (Oncogene Science,
3
p \\\ Manhasset, New York). Anti-PEP-2 specifically rec-
24 \ \ ognizes peptide sequence T P T P T Q F L C P K N
1 present in viralJun, and is crossreactive with mouse c-
Jun. After incubation with "25I-protein A, ifiters were
0 0.5 1 2 3 4 5 6 7 8 subjected to autoradiography and X-ray films were
Time of TPA Treatment (hr) scanned by densitometry analysis.
Figure 3 shows a representative time course exper-
iment ofTPA treatment in P+ Cl 41 and P- Cl 30 cells
over24 hr. As was the case forjunmRNA, Jun protein
was observed at significantly lower levels in the P- Cl
RE 2. TPA differentially induces c-jun but not c-fos mRNA 30 cells than in the P+ Cl 41 cells at time points ex-
,cumulation in P+ and P- cells. Promotion-resistant (P-) and amined. Basal levels were approximately 5-fold lower
romotion-sensitive (P-) JB6 cells were grown to near-conflu- in the P- cells than in the P+ cells, and induced levels
ice in 5% serum in T150 flasks and then switched to 2% serum ranged from 2- to 10-fold lower during the time course.
tr 24 hr. The cells were treated with 10 ng/mL TPA (16 nM), +
Lrvested by trypsinization and centrifugation, and total RNA In the P cells, TPA iduced a rapid accumulation of
as extracted at the indicated times as described previously Jun protein within 30 min, followed by a decline over
5). RNA (10 ,ug/sample) was subjected to electrophoresis and the duration of the experiment; in the P cells a delay
orthern blot analysis (45) using v-jun or v-fos cDNA probes in the onset ofinduction was observed In both cell lines
ifts of P. Vogt and T. Curran, respectively) labeled with 32P
ythe randompriming method (Pharmacia). The relative levels Jun protei levels declied by 24 hr of TPA treatment.
Ic-jun mRNA (upper panel) and c-fos mRNA (lower panel) These datasupport the hypothesis that control ofJun
ere determined by densitometric analysis ofthe resulting au- protein levels inJB6 P' and P- cells is pretranslational
radiographs. c-jun mRNA levels areexpressed as values rel- and is most likely caused by differential accumulation
tive to the levels in untreated P' Cl 41 cells (i.e., relativejun
iRNA = 1.0 for Cl 41 at T = 0), and c-fos mRNA levels are ofjun mRNA. The results provide further support for
tpressedrelative tothe values inuntreated P- Cl30cells. The the hypothesis that differences in transactivation and
ata shown are the means ofthree to four experiments + SE, promotion sensitivity in the P' and P cells mayin part
ccept for the following points. Forc-jun: P' value at 0.5 hr (n be explained by differences injun mRNA and Jun pro-
2); 8 hr and 24 hr values (n = 1). For c-fos: 0.5 hr values (n tein accumulation andareconsistentwiththepossibility
2);8 hr value (n
= 1). that threshold Jun levels are required for transactiva-
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FIGURE 3. Time course ofTPA treatment and measurement ofc-
Jun protein levels in P+ and P- Cells. P+ Cl 41 cells and P- Cl
30 cells were TPA treated and harvested as described in Figure
2. Nuclei were prepared as described by Bos et al. (39) with
minor modifications (37). Per sample, 1 x 106 nuclei were run
in 10% Laemmli SDS polyacrylamide gels (39,40), transferred
by Western blotting onto BA85 nitrocellulose filters (Schleicher
and Schuell), and blotted with 5 ,ug/mL affinity purified rabbit
anti PEP-2 antiserum, according to the methods of Towbin et
al. (41), with modifications (37), followed by 5 x 10' cpm/mL
126I protein A (PRI/FCRF). Filters were exposed overnight to
Kodak XAR film and resulting autoradiograms were scanned in
an LKB Ultroscan XL Densitometer. The representative ex-
periment in Figure 3 shows results from densitometric analysis
of P+ and P- cells treated with TPA over a 24-hr time course.
Data are plotted as relative optical intensity, using a value of
1.0 for the TPA-untreated 0 time control in the P+ Cl 41 cells.
tion and possibly neoplastic transformation. Since tran-
sactivation responses appear topersistbeyond the time
course ofJun induction it is possible that, while a Jun
threshold may be necessary, it may not be sufficient for
transactivation orpromotioninthis system. Theprecise
role and mechanisms of control of cellular responsive-
ness by the AP-1 complex continue to be investigated.
Differential Expression of an 80-
kDa/pI 4.5 Protein during
Preneoplastic Progression
Previous investigations in this laboratory demon-
strated adifferentialbasal and induced levels ofphos-
phorylated ofp80 duringpreneoplastic progression in
JB6 cells (46). Two-dimensional gel electrophoresis of
proteins labeled in vivo with 2P-orthophosphate
showed high levels ofaphosphorylated 80 kDa/pI 4.5
protein in P- cells, intermediate levels in P+ cells,
Mrx 10-3
9.7
688
28S-
18-
+ p80
-No 2.6 kb
FIGURE 4. Differential expression ofp80 mRNA hybridizing to a
putative p80 clone from JB6 cells. (Top panel) Mouse JB6 cell
clone 30 (P-), 41 (P+), or RT101 (Tx) were lysed in Laemmli
buffer (40) and loaded onto an 10% SDSpolyacrylamide gel. The
gel was immunoblotted with p80 peptide antiserum provided by
D. Kligman (47) (diluted 1:500) as described in Figure 3. Each
lane contained an equivalent amount ofcellular protein (20 p.g).
(Bottom panel) P-, P+, and transformed total cellular RNAs
were isolated according to the procedure of Deeley et al. (51)
and subjected to Northern analysis as described in Simek et al.
(20). Each lane contained 10 ,ugoftotal cellular RNA. Theifiters
were exposed to Kodak XAR film for 2 days.
and essentially none in neoplasticallytransformed de-
rivatives ofJB6 cells (46). Exposure to TPA caused
elevated p80 phosphorylation in P- and P+ cells, but
not in transformed cells. These results raised the
question of whether this differential regulation was
occurring at the pretranslational or posttranslational
level. To determine whetherthe regulationwasatthe
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FIGURE 5. TPA treatment causes an increase in p80 phosphorylation but not in p80 synthesis. JB6 clone 30 (P-) cells were labeled with
32P orthophosphate (200 ,uCi/mL) for 2 hr. The cells were treated with TPA (10 ng/mL) for various times. The cells were lysed in
either TNT buffer (0.2M NaCl 0.02 M Tris, 1% Triton X-100) and (A) immunoprecipitated with either preimmune or immune p80
peptide antiserum or (B) lysed in Laemmli buffer and immunoblotted as described in Figure 4. Samples were loaded onto a 10%
polyacrylamide gel. Panel A was dried and exposed to Kodak XAR film for 24 hr. Lanes 1, 3, 5, 7, and 9 preimmune; lanes 2, 4, 6, 8,
and 10, p80 peptide antiserum.
level of p80 synthesis, proteins from cell lysates of
JB6 P-, P+ and transformed cells were analyzed by
immunoblotting with apeptide antiserum (47) specific
for p80. As shown in the top panel of Figure 4, dif-
ferentialexpression ofp80proteinwasobserved, with
highlevels ofexpression in P- cells, intermediate lev-
els in P+ cells, and little or no expression in neoplast-
ically transformed cells. Similar results were ob-
served when a second set of independently derived
JB6P, P+ andtransformed clonalvariantswere ana-
lyzed.
A p80 cDNA which had been cloned by p80 peptide
antibody screening (20) was used to analyze JB6 cel-
lular p80 mRNA expression and to determine the ex-
tent to which p80 protein levels might be limited by
p80 mRNA concentration. As shown in the bottom
panel of Figure 4, when this p80 clone was used as a
probe against P- and P+ total cellular RNA, a single
2.6-kb band was observed, but little or no hybridi-
zation was seen with RNA from transformed cells.
Densitometric analysis from three experiments
showed the mean value forthe hybridizingband in P+
RNA was 50 + 2% and transformed RNA was 2.5 +
0.4% of the P- RNA value. This pattern was nearly
identical to that observed for the differential expres-
sion of p80 protein in these cells, indicating that in-
tracellular p80 protein concentration is regulated by
the levels ofp80 mRNA.
To determine whether TPA induces p80 phospho-
rylation and thereby test the hypothesis that p80 is a
PKC substrate, TPAtreatedJB6 P- celllysates were
immunoprecipitated withp80peptide antiserum. Fig-
ure 5A shows the pattern of p80 phosphorylation in
JB6 P- cells treated with TPA for 0, 2, 5, 8, and 24
hr. This experiment showed an increase in p80 phos-
phorylation with a 6-fold maximum at 2 hr after ini-
tiation ofTPA treatment (lane 4) that persisted for 5
hr (lane 6) and returned to basal levels by 24 hr (com-
pare lanes 10 and 2). This time course was comparable
to studies done in this laboratory (13) and by others
(48) not usingp80 antibody. The decreaseinp80phos-
phorylation occurred after 24 hr of TPA treatment
was paralleled in JB6 cells by a decrease in protein
kinase C activity and concentration (data not shown).
This result correlated with findings demonstrating
that treatment of cells with phorbol esters leads to
progressive downmodulation of phorbol ester recep-
tors (49) followed by disappearance ofprotein kinase
C activity (50). Thus, phosphorylation of p80 in JB6
cells is dependent on protein kinase C, and p80 may
or may not be a direct protein kinase C substrate.
To determine whetherthe observed increase in p80
phosphorylation reflected an increase in synthesis or
was controlled posttranslationally, JB6 P- cells were
exposed to TPA for 0.5, 1, 4, and 24 hr. Cell lysates
were then analyzed by immunoblotting for levels of
p80, using p80 peptide antiserum. The results ofthis
experiment are shown in Figure 5B. The level ofp80
did not increase after tumor promoter treatment but
actually appeared to decrease after prolonged TPA
exposure (24 hr). Shorter TPA exposure times were
also tested and again showed no increase in p80 syn-
thesis. The results from this experiment confirmed
that p80 synthesis was not increased by exposure to
116AP-1 AND P80 IN PRENEOPLASTIC PROGRESSION OF JB6 CELLS 117
TPA. In addition, total cellular RNA, isolated from
P- cells after TPA treatment for 0, 4, and 24 hr,
showed no difference in the level of p80 hybridizing
RNA (data not shown). Therefore, this study indi-
cates that TPA treatment specifically induces the
phosphorylation and not the synthesis ofthe p80 pro-
tein.
Conclusions
Regulation ofc-jun expression in response to TPA
andthesubsequent activationofaspecificsetoftarget
genesinresponsetoAP-1 mayplayapartinthetumor
promotion process. A number of phorbol ester and
growth factorinducible genes have been found to con-
tain TREs in their promoter regions, and their
expression is believed to be regulated via binding of
AP-1 to this promoter element. These genes include
stromelysis/transin (30,53) and collagenase (30,54),
proteases that may play a role in tumor invasiveness
and metastasis, metallothionein IIA (30), and inter-
leukin-2 (55). In addition, AP-1 is thought to be in-
volved in the positive autoregulation ofc-jun (56) and
in both positive and negative autoregulation of c-fos
(57-60). Thus, differencesintumor-promoter-induced
gene activation by the AP-1 transcription factor be-
tween P+ and P- cells may lead to different patterns
of expression of key effector genes. The defective
APl-dependent transactivation observed in P- cells
mayaccount fortheirpromotion-resistant phenotype.
Relevant target genes for the promotion process in
these cells remain to be identified.
In addition to transiently regulated genes, certain
genes are constitutively switched on or switched off
during preneoplastic progression (61,62). The 80 kDa
protein observed in JB6 cells appears to be such a
negatively regulated protein. The fact that p80 levels
decrease as cells progress toward the neoplastic end
point is compatible with itspostulated role as a tumor
suppressor. Whether p80 is coordinately regulated
by, or with, the AP-1 protein via signals transduced
by protein kinase C is currently unknown. Further
investigations are underwayto elucidate whetherand
by what mechanisms AP-1 and p80 modulate suscep-
tibility to transformation promotion and progression
to the neoplastically transformed cellular phenotype.
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